SCHEMBL6079912

SCHEMBL6079912

O=C(O)c1nc2c(O)cccc2c(O)c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.50
ESR2 Q92731 1/20 0.50
PARP1 P09874 2/20 0.49
TNKS O95271 1/20 0.49
TNKS2 Q9H2K2 1/20 0.49
CCR6 P51684 1/20 0.46
CYP1A2 P05177 2/20 0.44
KDM4E B2RXH2 4/20 0.43
KDM4A O75164 1/20 0.43
RAB9A P51151 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
HIF1AN Q9NWT6 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DHODH Q02127 3/20 0.42
LMNA P02545 2/20 0.42
PDE10A Q9Y233 1/20 0.42
KMT2A Q03164 2/20 0.41
RNASEH1 O60930 1/20 0.41
ERCC1 P07992 1/20 0.41
FEN1 P39748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079746 0.88 PARP1 (0.48) ESR1ESR2PARP1TNKSTNKS2
SCHEMBL6079956 0.79 KDM4E (0.44) ESR1ESR2PARP1TNKSTNKS2
SCHEMBL6080384 0.79 KDM4E (0.46) PARP1TNKSTNKS2CCR6CYP1A2
SCHEMBL11879927 0.78 ESR1 (0.50) ESR1ESR2PARP1TNKSTNKS2
SCHEMBL13313367 0.73 ESR1 (0.72) ESR1ESR2PARP1TNKSTNKS2
SCHEMBL11815134 0.73 CYP1A2 (0.42) ESR1ESR2PARP1TNKSTNKS2
SCHEMBL31109172 0.72 SMN1; SMN2 (0.55) KDM4EDHODHLMNAPDE10ARNASEH1
SCHEMBL6080782 0.72 DHODH (0.50) KDM4EKDM4ADHODHPDE10AKMT2A
SCHEMBL6080749 0.71 CYP1A2 (0.54) PARP1TNKSTNKS2CCR6CYP1A2
SCHEMBL13958056 0.71 CCR6 (0.68) CCR6CYP1A2KDM4EKDM4ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP disclosed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL ESR1 4820/4885ESR2 4859/4885PARP1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.